This is the Quild daily, highlighting one early-stage startup that has statistically significant signals of becoming a unicorn. Entos combines machine learning and automated chemistry to revolutionize small-molecule therapeutics design. Traditional therapeutic discovery is highly complex and entails prolonged timelines, vast training data needs and sub-optimal accuracy. Entos is eradicating these challenges with its cutting-edge OrbNet platform, an AI-driven drug-development process that creates a thousand-fold acceleration in molecular properties prediction with 100x less training data required.
Quild #16: Entos
Quild #16: Entos
Quild #16: Entos
This is the Quild daily, highlighting one early-stage startup that has statistically significant signals of becoming a unicorn. Entos combines machine learning and automated chemistry to revolutionize small-molecule therapeutics design. Traditional therapeutic discovery is highly complex and entails prolonged timelines, vast training data needs and sub-optimal accuracy. Entos is eradicating these challenges with its cutting-edge OrbNet platform, an AI-driven drug-development process that creates a thousand-fold acceleration in molecular properties prediction with 100x less training data required.